Coverage by:

Shaw and Partners

Darren Vincent

Bell Potter

 Tanushree Jain

H.C. Wainwright & Co.

 Joseph Pantginis

  • Shaw and Partners

    24 November 2017

    BNC101 Shows More Encouraging Results Ahead of its Expected Monetisation

    Analysts: Darren Vincent, Matthew Johnston

    Download PDF

BELL POTTER 

2 November 2017

Initial Phase 1 BNC101 data should assist ongoing partnering discussions

Analyst: Tanushree Jain 

BELL POTTER

18 August 2017

FY17 results ahead of our forecasts 

Analyst: Tanushree Jain

  • H.C. Wainwright & Co.

    17 August 2017

    FY17 Results: BNC210 Excitement Continues to Grow for CNS; Oncology Visibility Soon Could Help BD Efforts; Reiterate Buy

    Analyst: Joseph Pantginis

    Download PDF

  • Rodman & Renshaw

    13 July 2017

    Management Meetings Continue to Highlight Disconnect Across Pacific: Reiterate Buy

    Analyst: Joseph Pantginis

    Download PDF

  • Shaw and Partners

    28 April 2017

    3Q17; Merck Payments, Immuno-Oncology progress & 210 Negotiations

    Analyst: Darren Vincent

    Download PDF

  • Rodman & Renshaw

    27 March 2017

    Our Chat Points to Very Active Partnering Discussions; Analyst Day Recap;

    Reiterate Buy

    Analyst: Joseph Pantginis

    Download PDF

  • Rodman and Renshaw

    20 March 2017

    Initiating Coverage:

    We Feel Lots Calmer Talking BNC210 and Bionomics: Initiating at Buy With A$2 PT

    Analyst: Joseph Pantginis

    Download PDF

BELL POTTER

22 February 2017

We continue to see deep value

Analyst: Tanushree Jain 

BELL POTTER

6 February 2017

CNS franchise validated, US$10m milestone triggered on initiation of trial by Merck

Analyst: Tanushree Jain

BELL POTTER

22 September

BNC210 Shines in Phase 2 GAD Trial, Partnering Prospects Strengthen

Analyst: Tanushree Jain 

BELL POTTER

5 September 2016

Strong Turnaround prospects, we see deep value

Analyst: Tanushree Jain

BELL POTTER

30 June 2016

BNC210 program expanded with start of PTSD trial

Analyst: Tanushree Jain

BELL POTTER

24 June 2016

On track to report General Anxiety Disorder trial results in 3Q16

Analyst: Tanushree Jain

BELL POTTER

16 June 2016

Bionomics announces new Board appointments

Anaylst: Tanushree Jain

BELL POTTER

2 May 2016

BNC105 looks well-suited for an immuno-oncology combination study

Analyst:  Tanushree Jain

BELL POTTER

2 March 2016

Long terms growth prospects intact, stock oversold

Analyst: Tanushree Jain

BELL POTTER 

8 December 2015

BNO raises capital to fund new Phase II BNC210 trial

Analyst: Tanushree Jain 

BELL POTTER

8 October 2015

Merck becomes a shareholder, Pain collaboration extended

Analyst: Tanushree Jain

BELL POTTER

29 September 2015

Bionomics Strengthens its Board

Analyst: Tanushree Jain

BELL POTTER

3 August 2015

Bionomics Strengthens its Executive Team

Analyst: Tanushree Jain

BELL POTTER

16 June 2015

BNC105 and immuno-oncology therapies - a synergistic combination

Analyst: Tanushree Jain

BELL POTTER

4 June 2015

BNC210 - A potential blockbuster in making

Analyst: Tanushree Jain

BELL POTTER

27 February 2015

New BNC105 Biomarker data builds confidence

Analyst: Tanushree Jain

BELL POTTER

29 September 2014

New BNC105 Biomarker data increase its attractiveness

Analyst: Tanushree Jain

  • SHAW STOCKBROKING

    29 September 2014

    Shaw Flashnote: Bionomics (BNO) - New data suggests BNC105 partnering will deliver significant $'s.

    Analyst: Darren Vincent

    Download PDF

BELL POTTER

24 September 2014

BNO makes strategic acquisition of Prestwick Chemical

Analyst: Tanushree Jain

BELL POTTER RESEARCH REPORT

26 August 2014

FY15 outlook - Well funded with more multimillion dollar deals to come

Analyst: Tanushree Jain

BELL POTTER RESEARCH REPORT

20 March 2014

BNC105 still has partnering prospects based on Phase II RCC Trial Results

Analyst: Tanushree Jain

BELL POTTER RESEARCH REPORT

2 August 2013

Deal inked with Merck is an appetiser, look forward to the main course

Analyst: Tanushree Jain

BELL POTTER RESEARCH REPORT 

16 April 2013

Great Expectations from BNC375

Analysts: Tanushree Jain/Stuart Roberts